3 Stocks I Saw on T...
Health Care: Drugs
Cadence Pharmaceuticals Inc. (CADX: NASDAQ)
$2.74 0.04 | 1.29%
06/04/12 - 03:44 PM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | n.a. | 75.30 | 17.70 |
| P/E High - Last 5 Yrs | n.a. | n.a. | 67.70 |
| P/E Low - Last 5 Yrs | n.a. | n.a. | 12.50 |
| Beta | 1.30 | 0.58 | 0.98 |
| Price to Sales (TTM) | 9.52 | 4.62 | 1.42 |
| Price to Book (MRQ) | 2.33 | 3.44 | 2.41 |
| Price to Tangible Book (MRQ) | 2.68 | 6.74 | 5.08 |
| Price to Cash Flow (TTM) | -2.60 | 26.10 | 9.80 |
| Price to Free Cash Flow (TTM) | -3.10 | 48.80 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.00 | 0.50 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 0.20 | 2.20 |
| Dividend 5 Yr Growth Rate (%) | n.a. | n.a. | -0.76 |
| Payout Ratio (TTM) | 0.00 | 3.00 | 30.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | 2,186.00 | 9.90 | 11.80 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | n.a. | 7.70 | 9.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | n.a. | 9.03 | 1.79 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS - 5 Yr Growth Rate (%) | n.a. | n.a. | -1.66 |
| Capital Spending - 5 Yr Growth Rate (%) | 8.34 | -4.13 | -1.17 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 5.30 | 2.90 | 1.10 |
| Current Ratio (MRQ) | 5.50 | 3.50 | 1.60 |
| LT Debt to Equity (MRQ) | 0.26 | 0.41 | 0.82 |
| Total Debt to Equity (MRQ) | 0.29 | 0.45 | 0.96 |
| Interest Coverage (TTM) | n.a. | 6.20 | 5.50 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | 41.20 | 84.10 | 46.90 |
| Gross Margin - 5 Yr Avg | 57.90 | 83.50 | 47.70 |
| EBITD Margin (TTM) | n.a. | 27.30 | 18.90 |
| EBITD - 5 Yr Avg | -2,111.69 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | n.a. | 14.10 | 12.10 |
| Pre-Tax Margin - 5 Yr Avg | n.a. | 10.60 | 10.30 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | -3.75 | 0.10 | 0.09 |
| Net Profit Margin - 5 Yr Avg | n.a. | 5.30 | 7.00 |
| Return on Assets (TTM) | -62.00 | 4.70 | 3.10 |
| Return on Assets - 5 Yr Avg | -56.30 | 2.20 | 2.50 |
| Return on Investment (TTM) | -72.00 | 6.10 | 7.90 |
| Return on Investment - 5 Yr Avg | -68.10 | 2.80 | 6.50 |
| Efficiency | |||
| Revenue/Employee (TTM) | 110,682.00 | 701,747.00 | 449,376.00 |
| Net Income/Employee (TTM) | -415,100.00 | 83,589.00 | 39,003.00 |
| Receivable Turnover (TTM) | 12.10 | 5.80 | 7.60 |
| Inventory Turnover (TTM) | 4.80 | 1.30 | 8.30 |
| Asset Turnover (TTM) | 0.20 | 0.40 | 0.40 |
Portfolios with CADX
- Portfolio NameUser Type
- Contributor8 Stocks Below $10 To Avoid
- Contributor10 Most Shorted Stocks in B...
- ContributorRelative Strength Stocks 09...
- Usergrainey Portfolio 1
- Useryourguess Portfolio 1
- Userlives288
- UserCarl Nicola Portfolio 1
- Userron stewart
Latest CADX Headlines from TheStreet
- 8 Stocks Under $10 to Avoid at All Costs 12.23.11 | 12:12 pm
- Pacira: Exparel Approval Easy, Selling Painkiller Harder Challenge 10.31.11 | 11:10 am
- 5 Stocks Showing Relative Strength in a Weak Market 09.22.11 | 02:09 pm
- Biotech Stock Mailbag: Cadence Pharma 03.11.11 | 07:03 am
- Biotech Sector Weekly Rewind 11.06.10 | 09:11 am
- Cadence CEO Discusses Q3 2010 Results - Earnings Call Transcript 11.05.10 | 02:11 pm
- Cadence: When A Drug Approval Sinks Stock 11.03.10 | 10:11 am
- FDA Ends October With Drug Approvals, Rejection 11.01.10 | 07:11 am
- Biotech Stock Mailbag: Exact Sciences 10.15.10 | 07:10 am
- 21 Drugs Facing FDA Approval Decisions 08.31.10 | 08:08 am
Press Releases for CADX
- Cadence Pharmaceuticals Announces Proposed Public Offering Of Common Stock - PR Newswire 11.08.10 | 06:11 am
Partner Headlines for CADX
- Cadence: Not Altering Sales Projections Or Rating In Aftermath Of Product Recall - Seeking Alpha 02.08.12 | 09:02 am
- Cadence Pharmaceuticals: Good For Patients, Bad For Investors - Seeking Alpha 12.26.11 | 08:12 am
- Wedbush Lowers Cadence PT to $10 from $15 - Benzinga 11.23.11 | 01:11 pm
- Company News for November 18, 2011 - Corporate Summary - Zacks 11.18.11 | 10:11 am
- Options Brief: Cadence Pharmaceuticals - Benzinga 07.15.11 | 01:07 pm
- Cadence: Not Unduly Concerned About ANDA Filing Against Ofirmev - Seeking Alpha 07.05.11 | 09:07 am
- 6 Speculative Biotech Stocks Smart Money Loves - Seeking Alpha 05.23.11 | 09:05 am
- Top 15 Most Undervalued Biotech Stocks By Analyst Target Price - Seeking Alpha 04.08.11 | 03:04 pm
- Future Biotech Superstars - Seeking Alpha 03.30.11 | 09:03 am
- Cadence Pharmaceuticals: A Rising Star - Seeking Alpha 03.13.11 | 09:03 am
